The antigen recognition part of the antibody and the common part of the antibody both function in mediating the anti-tumor response. Pink is the CD40-binding domain comprised of the variable regions of the antibody. Green is the common portion that includes the heavy chain, which binds to Fc receptors. Mutations that affect the Fc receptor-binding portion alter the anti-tumor immune response. [Credit: Heather McDonald]
Read more about optimizing this CD40 antibody:
N. R. Gough, Optimizing anti-tumor therapies using engineered antibodies. BioSerendipity (18 September 2018) https://www.bioserendipity.com/optimizing-anti-tumor-therapies-with-engineered-antibodies/